RxDoctor Payments Data

Keisha Jones, MD

Urogynecology and Reconstructive Pelvic Surgery · Springfield, MANPI 1316143514

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (54.8%), food and beverage and gifts — rather than concentrated in one kind of arrangement. Coloplast accounts for 85.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $2,369 and has fallen 95.3% since, to $111 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in MA, where the typical reported total is $2,944.

$2,944in general payments, 2019–2025

Across 15 payments — averaging $196.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$3K
  • Medtronic$230
  • Boston Scientific$101
  • Applied Medical Resources Corporation$66
  • Caldera Medical, Inc$35
$195,638in research payments, 2019–2025

Across 40 payments — averaging $4890.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coloplast$196K

What the payments were for

  • Travel & lodging$1,61455%
  • Food & beverage$1,29544%
  • Gifts$351%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,944 in reported general payments places this provider in the 50th percentile of 35 urogynecology and reconstructive pelvic surgery providers in Massachusetts.

See all urogynecology and reconstructive pelvic surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$151,358
Medicare patients
374
Services billed
892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron323$235,777
MyrbetriqMirabegron336$197,931
Estradiol250$17,006
Mirabegron ErMirabegron23$10,390
Trospium Chloride ErTrospium Chloride59$5,943
Methenamine Hippurate59$4,636
Solifenacin Succinate55$2,421
Darifenacin ErDarifenacin Hydrobromide23$2,362
Clobetasol Propionate28$2,322
Tolterodine Tartrate ErTolterodine Tartrate16$1,783
Fesoterodine Fumarate ErFesoterodine Fumarate18$1,434
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst100$1,356
Oxybutynin Chloride ErOxybutynin Chloride56$1,041
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim31$122
Oxybutynin Chloride13$72

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →